US 10/22 E-cigarette seizures: FDA targets big brands in 'deterrent' move, inter-agency enforcement may become the norm

Oct.25.2024
US 10/22 E-cigarette seizures: FDA targets big brands in 'deterrent' move, inter-agency enforcement may become the norm
FDA and CBP jointly seized 3 million unauthorized e-cigarette products worth $76 million, the largest bust in FDA history.The FDA's multi-agency enforcement actions against popular major brands in certain markets require not only short-term measures, such as obtaining Submission Tracking Numbers (STNs), but also long-term planning. Companies are advised to incrementally improve compliance capabilities, establish dedicated compliance departments, and conduct regulatory research to mitigate potent

The US Food and Drug Administration (FDA) and US Customs and Border Protection (CBP) recently conducted a joint operation that resulted in the seizure of approximately 3 million unauthorised e-cigarette products with an estimated retail value of up to $76 million. This is the largest amount ever seized by the FDA. In response to this operation, 2Firsts spoke to several lawyers and compliance professionals who have long monitored the e-cigarette industry.

 

Tang Shunliang, partner at Tianyuan Law Firm and a legal expert in new tobacco areas such as e-cigarettes, and Zheng Zhi, PMTA certification consultant, also discussed their observations and assessments of the event.

 

In the face of a larger scale joint official action and intensified crackdown, they expressed that companies must not only apply for an STN number in the short term as a reaction measure, but also plan for the long term. By gradually improving compliance capabilities and establishing compliance departments for regulatory research, companies can avoid potential legal risks and market losses in the future.

 

 

Industry lawyer warns of 'crackdown as a deterrent' to enforcement in the sector

 

 

Tang Shunliang, a partner at Tianyuan Law Firm and a legal expert on new tobacco products such as e-cigarettes, emphasised that the recent joint enforcement action by the FDA and US Customs sends a strong deterrent signal in addition to its regulatory significance.

 

Tang noted that this enforcement action was not without "warning signs". The FDA has issued numerous warning letters in recent years as part of its Premarket Tobacco Product Application (PMTA) process, signalling a steady increase in regulatory scrutiny of the e-cigarette industry.

 

While the FDA does not have a nationwide enforcement team, it has targeted popular brands in key markets. Tang described this approach as "enforcement as a deterrent", noting that non-compliance by major brands has a broader impact on the market and consumers.

 

"The announcement specifically naming 'GEEKBAR' reflects the FDA's strategy to focus on high-impact brands to regulate the entire industry through such targeted actions," Tang explained.

 

According to Tang, the FDA-Customs joint enforcement was not a random selection, but a calculated move. The compliance of big brands has a lot of influence, which makes them prime targets. Unlike China's nationwide tobacco control network, the FDA's enforcement prioritises large companies as a form of warning.

 

Tang also provided legal context, explaining that the US lacks a comprehensive enforcement network for e-cigarette regulation. Therefore, cooperation between the FDA and Customs is filling this gap. He expects such inter-agency actions to become routine, especially targeting e-cigarette companies that evade duties by misclassifying goods and values.

 

 

PMTA compliance experts: PMTA enters critical phase, companies should respond proactively

 

 

Zheng Zhi, a PMTA compliance consultant with expertise in FDA tobacco regulations, also provided an in-depth analysis of this latest enforcement action.

 

Zheng highlighted that while the FDA began its compliance review of e-cigarette products in 2019, the process has been relatively slow due to the wide range of products involved. Despite the proximity of the 2024 enforcement action to the US presidential election, Zheng noted that these actions are the result of the natural progression of compliance measures rather than purely political motivations.

 

"The FDA's inaction or slow PMTA process has long drawn criticism from multiple fronts. Now, with improved regulations, streamlined procedures and key roles filled, the FDA is ready to accelerate compliance efforts. This action is both a reflection of regulatory pressure and a milestone before the election," commented Zheng.

 

He specifically mentioned that many companies are currently relying on Submission Tracking Numbers (STNs) as a temporary safeguard. However, this approach won't ensure market compliance in the long run. Over time, FDA requirements will increase and companies will need to obtain more advanced compliance certifications, such as Acceptance Letters or File Letters, which will present new challenges.

 

"In my opinion, STNs are only a short-term measure. In the future, more companies will need to meet higher compliance standards, such as obtaining PMTA Acceptance Letters or File Letters. This will raise the bar in terms of resources and skills, making it manageable only for top-tier companies, while smaller companies may struggle to survive or will need to incrementally improve compliance to remain competitive," he explained.

 

 

Future outlook: Enforcement likely to evolve into coordinated inter-agency effort

 

 

Both Tang Shunliang and Zheng Zhi addressed potential enforcement trends regarding misclassification of e-cigarette products and customs evasion.

 

Zheng noted that the recent cooperation between US Customs and the FDA may be just the beginning. As more federal agencies get involved, the regulatory landscape for the e-cigarette industry is expected to become more comprehensive and stringent.

 

"Customs' role may extend beyond simply seizing illegal products; it may increasingly work with the Department of Justice and other federal agencies to create a multi-layered regulatory network. For companies trying to enter the market through illegal means, this could mean no escape," Zheng said.

 

He believes that future US regulation of e-cigarettes will be tightened, with seizures only the first step. Actions involving "grey customs" could even lead to criminal charges. To mitigate such risks, Zheng emphasised the need for companies to accelerate compliance efforts by establishing dedicated compliance teams to ensure their products meet US and international regulatory standards.

 

"For e-cigarette companies with global ambitions - whether brand owners or manufacturers - setting up compliance departments and conducting regulatory research will be essential steps. Compliance is a systematic process, similar to the medical or pharmaceutical industries, and ignoring it could have disastrous consequences," Zheng stressed.

 

Both Tang and Zheng advised that companies need not only short-term solutions but also long-term strategies to gradually improve compliance and avoid potential legal risks and market setbacks.

 

"With US regulatory pressure increasing towards the end of the year, market entry now requires strict adherence to regulatory requirements. Only by raising compliance standards can companies hope to 'survive' in this highly competitive landscape," added Tang.

 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
The U.S. Food and Drug Administration (FDA) announced on May 5, 2026 that it authorized the marketing of four Glas electronic nicotine delivery system (ENDS) products through the premarket tobacco product application (PMTA) pathway. The authorized products are Classic Menthol, Fresh Menthol, Gold and Sapphire pods, each containing 50mg/ml, or 5%, tobacco-derived nicotine.
May.06 by 2FIRSTS.ai
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS submitted a comment letter to USTR in a proceeding examining unfair trade practices worldwide. The letter focuses on illicit nicotine products made in China and shipped to the United States in violation of U.S. law. NACS said the U.S. electronic nicotine delivery systems market has become dominated by illicit products, mainly disposable e-cigarettes manufactured in China and sold without the marketing authorization required by the U.S. Food and Drug Administration.
Apr.16 by 2FIRSTS.ai
Can hookah go institutional? A hookah company seeking to go public makes its case with capital, technology and regulation
Can hookah go institutional? A hookah company seeking to go public makes its case with capital, technology and regulation
2Firsts explored whether hookah can evolve into a more mature and governable category by interviewing Dubai-based hookah company AIR. AIR argues that strong margins, OOKA’s closed-system model and the prospect of differentiated regulation could support that shift. The larger question is whether this is simply AIR’s capital-markets narrative, or an early sign that competition, regulation and category boundaries in hookah are beginning to change.
Apr.02
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Researchers at the Chinese Academy of Sciences reconstructed nicotine biosynthesis in non-tobacco plants and yeast systems, highlighting how advances in synthetic biology could gradually reshape future nicotine production technologies and challenge regulatory frameworks built around tobacco-derived definitions.
Special Report
May.07
ITC Keeps Exclusion and Cease-and-Desist Orders in Place Against Stiiizy
ITC Keeps Exclusion and Cease-and-Desist Orders in Place Against Stiiizy
U.S. International Trade Commission has refused to pause the import and sales bans imposed on cannabis vape company Stiiizy while it appeals the agency’s patent infringement ruling in its dispute with Pax Labs.
Apr.07 by 2FIRSTS.ai